EMA’s Human Medicine Committee Supports Approval of Acoramidis in Treating Transthyretin Amyloid Cardiomyopathy
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has endorsed acoramidis for market authorization in the European Union. Acoramidis is an orally consumed, selective small-molecule stabilizer of transthyretin (TTR). It targets adult individuals diagnosed with […]